C₂N Diagnostics, a leader in advanced brain health diagnostics, is adding to its evidence-based legacy at the 2023 AAIC in Amsterdam July 16–20
C₂N continues to set a standard in innovation in Alzheimer’s disease diagnostics through numerous presentations by esteemed researchers and clinicians at AAIC. Join us in Amsterdam and be among the first to learn about exciting new data for the Precivity™ line of blood tests.
Hear it First! Sessions on C2N's Test Data
Multiple sessions and poster presentations will offer novel insights relating to the Precivity™ blood tests. These presentations include:
Perspective Session:
Advances in plasma Alzheimer's disease biomarkers
Tuesday, July 18 - 9:15 – 10:30 AM CEST, Hall 2
Featured Research Session:
Blood Biomarkers in Alzheimer’s disease
Tuesday, July 18 – 2:15 – 3:30 PM CEST, Hall 2
Plenary Session:
Amyloid Reduction and Evidence of Downstream Biomarker Modification
Wednesday, July 19 – 11:15 AM – 12:30 PM CEST, Hall 5
Featured Research Session:
Implementation of plasma AD biomarkers in diverse community-based and primary care settings
Wednesday, July 19 - 4:15 – 5:30 PM CEST, Hall 5
Poster Session:
#83156 BioHermes blood-based biomarker study topline results. Aβ 42/40 and p-tau181/217 blood-based biomarkers compared to amyloid PET and CSF in a diverse, community-based population
Monday, July 17, 2023
Other AAIC Sessions on Blood Biomarkers relating to the Precivity™ portfolio of tests:
Developing Session:
Target engagement and downstream effect on CSF MTBR-tau243 in DIAD
Sunday, July 16 - 8:00 – 8:45 AM CEST
Featured Research Session:
Novel insights into tau biology in AD and other tau pathologies
Monday, July 17 – 4:15 – 5:30 PM CEST, Hall 2
All sessions held at the RAI Centre Amsterdam.
Visit our C2N Booth #701
When entering the exhibit hall entrance, head to the right. We encourage you to click this link to schedule a meeting with our team
We look forward to seeing you in Amsterdam!
About C₂N Diagnostics, LLC
C₂N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C₂N strives to provide exceptional laboratory services and products in the field of brain health. C₂N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C₂N ’s assays have been used in over 100 Alzheimer’s disease research studies and disease-modifying therapy clinical trials in the U.S. and around the world. These studies include collaborations with leading academic institutions, pharmaceutical and biotech companies, National Institute on Aging, Alzheimer’s Association, and other non-profits and consortiums.
For the latest news and updates, please visit https://precivityad.com.